{"id":"dapt-reduction","safety":{"commonSideEffects":[{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Myocardial infarction"},{"rate":null,"effect":"Bleeding reduction (benefit, not adverse event)"}]},"_chembl":{"chemblId":"CHEMBL177969","moleculeType":"Small molecule","molecularWeight":"446.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rather than a single drug, DAPT reduction refers to protocols that limit dual antiplatelet therapy to shorter periods (typically 1–3 months instead of 12 months) in selected patients undergoing coronary stent placement. This approach aims to reduce bleeding complications while maintaining efficacy in preventing stent thrombosis, particularly in high-bleeding-risk patients or those requiring urgent surgery.","oneSentence":"DAPT reduction is a clinical strategy to shorten the duration of dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) after percutaneous coronary intervention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:43.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of bleeding risk in high-bleeding-risk patients undergoing percutaneous coronary intervention with stent placement"},{"name":"Patients requiring urgent surgery or procedures incompatible with prolonged antiplatelet therapy"}]},"trialDetails":[{"nctId":"NCT06521463","phase":"NA","title":"SIMPLAAFY Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-10-01","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":1857},{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT06916520","phase":"PHASE4","title":"Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)","status":"RECRUITING","sponsor":"J.P.S Henriques","startDate":"2025-11-13","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)","enrollment":300},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT05491200","phase":"PHASE4","title":"Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients","status":"RECRUITING","sponsor":"Research Maatschap Cardiologen Rotterdam Zuid","startDate":"2022-07-22","conditions":"ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy","enrollment":1656},{"nctId":"NCT06821191","phase":"PHASE4","title":"Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-03-10","conditions":"Coronary Artery Disease","enrollment":78},{"nctId":"NCT06871358","phase":"NA","title":"The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2024-09-01","conditions":"STEMI (STE-ACS), Primary PCI for STEMI","enrollment":40},{"nctId":"NCT03462498","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2018-04-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":3008},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT03218787","phase":"NA","title":"XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2017-07-19","conditions":"Coronary Artery Lesions","enrollment":2047},{"nctId":"NCT00963781","phase":"PHASE4","title":"Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2009-08","conditions":"Coronary Artery Disease, Coronary Thrombosis","enrollment":219},{"nctId":"NCT02567461","phase":"PHASE4","title":"Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-03","conditions":"Coronary Artery Disease","enrollment":80},{"nctId":"NCT02974777","phase":"PHASE4","title":"The IDEAL-PCI Extended Registry","status":"WITHDRAWN","sponsor":"Kaiser Franz Josef Hospital","startDate":"","conditions":"Coronary Arterioscleroses, Platelet Dysfunction Due to Drugs","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":455,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DAPT reduction","genericName":"DAPT reduction","companyName":"Kaiser Franz Josef Hospital","companyId":"kaiser-franz-josef-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAPT reduction is a clinical strategy to shorten the duration of dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) after percutaneous coronary intervention. Used for Reduction of bleeding risk in high-bleeding-risk patients undergoing percutaneous coronary intervention with stent placement, Patients requiring urgent surgery or procedures incompatible with prolonged antiplatelet therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}